Cargando…
细胞周期检测点激酶与肺癌耐药研究进展
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105604/ https://www.ncbi.nlm.nih.gov/pubmed/33910274 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09 |
Ejemplares similares
-
MicroRNA与肺癌顺铂耐药相关性研究进展
Publicado: (2014) -
非小细胞肺癌EGFR-TKIs耐药——小细胞肺癌转化的研究进展
Publicado: (2017) -
DNA损伤修复与肺癌顺铂耐药机制的研究进展
Publicado: (2011) -
肺癌干性样细胞与耐药
Publicado: (2022) -
STAT3在非小细胞肺癌耐药中的研究进展
Publicado: (2019)